GRCE vs RJF · $35.0M cap vs rev $15.91B
Grace Therapeutics, Inc. (GRCE) versus RJF (RJF) — a side-by-side from cached financials, not a winner call.
Grace Therapeutics, Inc. (GRCE) is a biotechnology company listed on US.
RJF (RJF) common stock.
GRCE does not have a complete income-statement cache yet.
Latest reported RJF revenue for 2025-09-30 was $15.91B. Net income was $2.13B. Revenue was up 6.6% from 2024-09-30 to 2025-09-30. RJF currently screens at market cap $0.
GRCE currently screens at market cap $35.0M. RJF currently screens at market cap $0.
Not investment advice. Open the GRCE and RJF stock pages for the full models.
Not investment advice.